Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes -: implications for cost-effectiveness analyses

被引:75
|
作者
van Valkengoed, IGM
Morré, SA
van den Brule, AJC
Meijer, CJLM
Bouter, LM
Boeke, AJP
机构
[1] Vrije Univ Amsterdam Med Ctr, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Sect Mol Pathol, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Immunogenet Lab, Amsterdam, Netherlands
[4] PAMM Inst, Lab Pathol & Med Microbiol, Eindhoven, Netherlands
关键词
mass screening; Chlamydia trachomatis; salpingitis; pelvic inflammatory disease; infertility; costs and cost analysis; ectopic pregnancy;
D O I
10.1093/ije/dyh029
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Cost-effectiveness analyses of screening programmes for asymptomatic Chlamydia trachomatis infection suggest that screening at low prevalences in the population is cost-effective. However, the decision models in these studies are based on assumptions about the risk of complications, which are derived from the literature. Incorrect assumptions may lead to under- or overestimation of the effectiveness of screening. The first objective of this paper is to evaluate the assumptions about the probability of complications after an asymptomatic C. trachomatis infection. The second objective is to calculate alternative rates by using available data on the incidence of complications. Methods We identified cost-effectiveness studies via Medline, and evaluated these for the evidence for the quoted probabilities. In addition, the probability of complications was calculated for Amsterdam from available registration data. Results In the three studies that were identified, the assumptions for the rates of pelvic inflammatory disease (PID) (clinical and subclinical) after C. trachomatis infection varied from 15% to 80%, and for ectopic pregnancy, tubal factor infertility, and chronic pelvic pain after PID from 5-25%, 10-20%, and 18-30%, respectively. The assumptions were based on data from high-risk populations, case-control data, and data not accounting for misdiagnoses. Using data obtained from local registrations, we estimated the probability of a clinical PID (0.43%), ectopic pregnancy (0.07%), and tubal factor infertility (0.02%) for women with a current infection. These estimates were consistently lower than the estimates based on the literature. Conclusions We argue that an overestimation of the current complication rates is likely. The effect of overestimation is potentially the greatest in populations with a low prevalence, since the currently assumed cost savings associated with screening may disappear when using more realistic estimates for complications.
引用
收藏
页码:416 / 425
页数:10
相关论文
共 50 条
  • [21] Systematic screening for Chlamydia trachomatis:: Estimating cost-effectiveness using dynamic modeling and Dutch data
    de Vries, R
    van Bergen, JEAM
    de Jong-van den Berg, LTW
    Postma, MJ
    VALUE IN HEALTH, 2006, 9 (01) : 1 - 11
  • [22] Cost effectiveness of screening for Chlamydia trachomatis:: a review of published studies
    Honey, E
    Augood, C
    Templeton, A
    Russell, I
    Paavonen, J
    Mårdh, PA
    Stary, A
    Stray-Pedersen, B
    SEXUALLY TRANSMITTED INFECTIONS, 2002, 78 (06) : 406 - 412
  • [23] Cost-effectiveness of screening swab or urine specimens for Chlamydia trachomatis from young Canadian women in Ontario
    Goeree, R
    Jang, D
    Blackhouse, G
    Chong, S
    Mahony, J
    Sellors, J
    Foy, A
    Chernesky, M
    SEXUALLY TRANSMITTED DISEASES, 2001, 28 (12) : 701 - 709
  • [24] Improving the cost-effectiveness of Chlamydia screening with targeted screening strategies
    Evenden, D.
    Harper, P. R.
    Brailsford, S. C.
    Harindra, V.
    JOURNAL OF THE OPERATIONAL RESEARCH SOCIETY, 2006, 57 (12) : 1400 - 1412
  • [25] COST-EFFECTIVENESS OF SCREENING FOR CHLAMYDIA USING DNA AMPLIFICATION
    GENC, M
    DOMEIKA, M
    MARDH, PA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (22): : 1741 - 1741
  • [26] Dynamic modelling for estimating the cost effectiveness of a Chlamydia trachomatis screening program
    de Vries, R
    van Bergen, JEAM
    Postma, MJ
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2004, 14 (04): : 47 - 47
  • [27] Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics -: A cost-effectiveness analysis of three strategies
    Howell, MR
    Quinn, TC
    Gaydos, CA
    ANNALS OF INTERNAL MEDICINE, 1998, 128 (04) : 277 - +
  • [28] The Cost-Effectiveness of a Chlamydia Trachomatis Vaccination Program in Young Women in the United States
    Ditkowsky, Jared
    Rahman, Afsana
    Hammerschlag, Margaret
    Kohlhoff, Stephan
    Smith-Norowitz, Tamar A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB58 - AB58
  • [29] Availability of data for cost-effectiveness comparison of vision screening programmes
    Simonsz, Huibert Jan
    Kik, Jan
    Heijnsdijk, Eveline
    Mackey, Allison
    Carr, Gwen
    Horwood, Anna
    Fronius, Maria
    Carlton, Jill
    Uhlen, Inger
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [30] A population based dynamic approach for estimating the cost effectiveness of screening for Chlamydia trachomatis
    Welte, R
    Kretzschmar, M
    van den Hoek, JAR
    Postma, MJ
    SEXUALLY TRANSMITTED INFECTIONS, 2003, 79 (05) : 426 - 426